EpoS71E

EpoS71E is a **mutant variant of erythropoietin (Epo)** engineered to provide neuroprotective effects without inducing erythropoiesis and raising hematocrit to dangerous levels[1]. Specifically, S71E refers to a mutation at position 71 in the Epo protein—serine replaced by glutamic acid. EpoS71E has been studied in animal models of **Parkinson’s disease** and showed evidence of **enhanced axonal sprouting and normalization of dopaminergic tone**, though it did not protect substantia nigra neurons from toxin-induced loss[1]. The drug is delivered via **recombinant adeno-associated viral (rAAV) vectors**, typically by intramuscular injection for systemic expression[1]. Mechanistically, EpoS71E is a **non-erythropoietic erythropoietin mimetic** providing neurotrophic and neuroregenerative effects, likely through pathways involving neuronal sprouting and protection of dopaminergic function, without activating the canonical erythropoietic axis. Current research indicates it may mitigate motor impairment in Parkinsonism models by promoting axonal sprouting rather than directly preventing neuronal cell death[1]. Developer information has not been explicitly stated in the published literature[1].

Other names

EpoS71EEpoS-71EEpoS 71E